Pangaea Oncology S.A. | Small-cap | Healthcare
€1.72
0.00%
| Pangaea Oncology Stock Comparison:
Pangaea Oncology vs Clinica Baviera S.APangaea Oncology vs EuroEspes S.APangaea Oncology vs Grifols, S.APangaea Oncology vs LaboratoriosPangaea Oncology vs Almirall S.APangaea Oncology vs IBEX 35 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 32.4M
Total Liabilities 9.6M
Shareholders Equity 22.8M
Debt to Equity 0.42

Cash Flow Metrics

Revenue & Profitability Trend

Pangaea Oncology Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i14.3M7.4M4.4M4.6M4.1M
Cost of Goods Sold i-21.0K-74.1K255.5K-568.6K-512.7K
Gross Profit i14.3M7.5M4.1M5.2M4.6M
Gross Margin % i100.1%101.0%94.1%112.4%112.5%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i4.2M3.1M1.3M786.9K691.1K
Other Operating Expenses i263.5K19.2K208.9K280.5K138.1K
Total Operating Expenses i4.4M3.1M1.5M1.1M829.2K
Operating Income i-2.0M-2.4M-2.2M-297.5K-1.5M
Operating Margin % i-14.0%-32.6%-50.3%-6.5%-37.8%
Non-Operating Items
Interest Income i--19.7K1.9K0
Interest Expense i301.3K127.0K189.4K252.9K186.0K
Other Non-Operating Income-----
Pre-tax Income i-1.7M-2.5M-2.8M-1.1M-1.9M
Income Tax i-495.7K1.3M-114.7K-456.5K-112.7K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-1.3M-4.8M-2.7M-641.9K-1.8M
Net Margin % i-8.9%-64.6%-62.4%-13.9%-42.7%
Key Metrics
EBITDA i509.2K-618.2K-1.2M365.5K730.3K
EPS (Basic) i-€-0.15€-0.09€-0.03€-0.09
EPS (Diluted) i-€-0.15€-0.09€-0.03€-0.09
Basic Shares Outstanding i-30144621304438192281696319000794
Diluted Shares Outstanding i-30144621304438192281696319000794

Income Statement Trend

Pangaea Oncology Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i3.3M1.4M7.1M2.0M251.5K
Short-term Investments i1.1M1.4M1.4M911.3K793.4K
Accounts Receivable i7.3M5.8M3.7M3.6M2.8M
Inventory i270.6K283.0K234.7K400.8K427.1K
Other Current Assets-----36
Total Current Assets i13.1M9.8M13.3M7.5M5.5M
Non-Current Assets
Property, Plant & Equipment i3.4M2.9M2.4M1.8M1.8M
Goodwill i17.9M18.6M10.8M8.3M7.0M
Intangible Assets i12.9M12.1M9.6M8.2M7.0M
Long-term Investments-----
Other Non-Current Assets-----
Total Non-Current Assets i19.3M18.7M15.1M13.3M11.5M
Total Assets i32.4M28.4M28.4M20.8M17.0M
Liabilities
Current Liabilities
Accounts Payable i2.2M2.3M862.7K736.2K1.2M
Short-term Debt i3.9M3.5M1.5M1.6M3.0M
Current Portion of Long-term Debt-----
Other Current Liabilities129.5K---
Total Current Liabilities i7.0M6.9M2.7M3.2M4.6M
Non-Current Liabilities
Long-term Debt i1.7M1.9M2.3M3.3M3.8M
Deferred Tax Liabilities i808.5K987.0K292.9K313.4K239.6K
Other Non-Current Liabilities-----
Total Non-Current Liabilities i2.6M2.9M2.6M3.6M4.0M
Total Liabilities i9.6M9.7M5.3M6.8M8.7M
Equity
Common Stock i688.3K609.8K609.8K450.7K374.5K
Retained Earnings i-13.3M-11.7M-7.9M-4.5M-3.7M
Treasury Stock i473.0K453.8K74.2K90.5K177.1K
Other Equity-----
Total Shareholders Equity i22.8M18.7M23.1M14.1M8.3M
Key Metrics
Total Debt i5.6M5.4M3.8M4.9M6.8M
Working Capital i6.1M2.9M10.6M4.3M880.7K

Balance Sheet Composition

Pangaea Oncology Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-1.8M-3.5M-2.8M-1.1M-1.9M
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i-2.0M120.2K-192.0K-1.0M-794.2K
Operating Cash Flow i-6.5M-5.4M-5.3M-4.1M-4.8M
Investing Activities
Capital Expenditures i-484.0K-256.0K-20.1K-26.7K-71.0K
Acquisitions i-67.8K-1.5M-120.1K-387.0K-150.0K
Investment Purchases i-0-605.4K-380.8K-
Investment Sales i313.0K246.9K0-30.8K
Investing Cash Flow i-238.8K-1.5M-745.6K-794.5K-190.2K
Financing Activities
Share Repurchases i-159.2K-2.2M0-16.4K0
Dividends Paid i-----
Debt Issuance i2.5M1.8M0453.0K5.5M
Debt Repayment i-1.9M-1.5M-1.7M-1.8M-3.5M
Financing Cash Flow i6.8M-1.1M9.5M5.1M2.0M
Free Cash Flow i-5.1M-2.7M-3.7M-2.5M-2.0M
Net Change in Cash i16.4K-8.0M3.5M199.4K-3.0M

Cash Flow Trend

Pangaea Oncology Key Financial Ratios

Valuation Ratios

Forward P/E -57.33
Price to Book 3.22
Price to Sales 4.09

Profitability Ratios

Profit Margin -37.18%
Operating Margin -20.63%
Return on Equity -29.97%
Return on Assets -9.44%

Financial Health

Current Ratio 1.16
Debt to Equity 23.04
Beta 0.12

Per Share Data

EPS (TTM) €-0.03
Book Value per Share €0.54
Revenue per Share €0.47

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
pang58.7M-3.22-29.97%-37.18%23.04
Clinica Baviera S.A 698.2M18.177.8346.33%13.51%70.72
EuroEspes S.A 6.3M---73.83%91.78%0.70
Grifols, S.A 7.8B29.191.694.99%4.00%126.87
Laboratorios 2.7B20.754.8825.01%17.66%22.50
Almirall S.A 2.2B102.601.511.45%2.02%26.47

Financial data is updated regularly. All figures are in the company's reporting currency.